AYJ Stock Overview
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Valneva SE Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €3.66 |
52 Week High | €7.88 |
52 Week Low | €2.98 |
Beta | 0.83 |
1 Month Change | 5.56% |
3 Month Change | -7.10% |
1 Year Change | -22.81% |
3 Year Change | -68.02% |
5 Year Change | 8.99% |
Change since IPO | -67.45% |
Recent News & Updates
Recent updates
Shareholder Returns
AYJ | DE Biotechs | DE Market | |
---|---|---|---|
7D | -8.7% | -5.9% | -1.7% |
1Y | -22.8% | -21.4% | -0.2% |
Return vs Industry: AYJ underperformed the German Biotechs industry which returned -19.9% over the past year.
Return vs Market: AYJ underperformed the German Market which returned 0.9% over the past year.
Price Volatility
AYJ volatility | |
---|---|
AYJ Average Weekly Movement | 6.6% |
Biotechs Industry Average Movement | 4.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AYJ has not had significant price volatility in the past 3 months.
Volatility Over Time: AYJ's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 676 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
AYJ fundamental statistics | |
---|---|
Market cap | €508.24m |
Earnings (TTM) | -€101.43m |
Revenue (TTM) | €153.71m |
3.3x
P/S Ratio-5.0x
P/E RatioIs AYJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AYJ income statement (TTM) | |
---|---|
Revenue | €153.71m |
Cost of Revenue | €160.77m |
Gross Profit | -€7.06m |
Other Expenses | €94.37m |
Earnings | -€101.43m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 07, 2024
Earnings per share (EPS) | -0.73 |
Gross Margin | -4.59% |
Net Profit Margin | -65.99% |
Debt/Equity Ratio | 137.9% |
How did AYJ perform over the long term?
See historical performance and comparison